Bio-Path Holdings Inc BPTH
Trading Information
- Previous Close Price
- $0.00
- Day Range
- $0.00–0.00
- 52-Week Range
- $0.00–0.11
- Bid/Ask
- $0.00 / $0.05
- Shares Outstanding
- 50.30M
- Market Cap
- $2,802.65
- Volume/Avg
- 205 / 44,138
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of a Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 10
- Website
- https://www.biopathholdings.com
Valuation
|
Metric
|
BPTH
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
BPTH
|
|---|---|
Quick Ratio | 0.00 |
Current Ratio | 0.07 |
Interest Coverage | −66.34 |
Quick Ratio
BPTH
Profitability
|
Metric
|
BPTH
|
|---|---|
Return on Assets (Normalized) | −514.93% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
BPTH
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|?q>%L$ | LOCK|Y<wZ! | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|r^?#L> | LOCK|%$dtQ | $83B | |||
| Moderna Inc
MRNA
| LOCK|ZFcCPlK | LOCK|wSR | $80B | |||
| argenx SE ADR
ARGX
| LOCK|Lx@^!$N | LOCK|?>T | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|!!&$LSw | LOCK|>? | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|v#l!Nv% | LOCK|w<TQW | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|sQLy%$# | LOCK|JFy@H | $28B | |||
| Incyte Corp
INCY
| LOCK|Jr&?>>T | LOCK|j$ | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|m$y$SS | LOCK|djp | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|F>?Ndbl | LOCK|B# | $14B |
United States